BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21154473)

  • 21. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
    Sun TM; Du JZ; Yao YD; Mao CQ; Dou S; Huang SY; Zhang PZ; Leong KW; Song EW; Wang J
    ACS Nano; 2011 Feb; 5(2):1483-94. PubMed ID: 21204585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient intracellular delivery of functional proteins using cationic polymer core/shell nanoparticles.
    Lee AL; Wang Y; Ye WH; Yoon HS; Chan SY; Yang YY
    Biomaterials; 2008 Mar; 29(9):1224-32. PubMed ID: 18078986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
    Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
    Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of disulfide core-crosslinked pluronic nanoparticles as an effective anticancer-drug-delivery system.
    Abdullah-Al-Nahain ; Lee H; Lee YS; Lee KD; Park SY
    Macromol Biosci; 2011 Sep; 11(9):1264-71. PubMed ID: 21717576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
    Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
    J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
    Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
    Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
    Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
    Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
    Wang Y; Xin D; Liu K; Zhu M; Xiang J
    Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
    Jin C; Bai L; Wu H; Tian F; Guo G
    Biomaterials; 2007 Sep; 28(25):3724-30. PubMed ID: 17509678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biamphiphilic triblock copolymer micelles as a multifunctional platform for anticancer drug delivery.
    Zhu W; Li Y; Liu L; Zhang W; Chen Y; Xi F
    J Biomed Mater Res A; 2011 Feb; 96(2):330-40. PubMed ID: 21171152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery.
    Sun TM; Du JZ; Yan LF; Mao HQ; Wang J
    Biomaterials; 2008 Nov; 29(32):4348-55. PubMed ID: 18715636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced antitumor efficacy of folate modified amphiphilic nanoparticles through co-delivery of chemotherapeutic drugs and genes.
    Yu B; Tang C; Yin C
    Biomaterials; 2014 Aug; 35(24):6369-78. PubMed ID: 24818887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers.
    Hofmanová J; Vaculová A; Hyzd'alová M; Kozubík A
    Oncol Rep; 2008 Feb; 19(2):567-73. PubMed ID: 18202809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
    Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
    J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multifunctional pluronic/poly(ethylenimine) nanoparticles for anticancer drug.
    Li N; Yang X; Zhai G; Li L
    J Colloid Interface Sci; 2010 Oct; 350(1):117-25. PubMed ID: 20598703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
    Odoux C; Albers A
    Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.